FutureChem Applies for IND for Phase 3 Clinical Trial of Radiopharmaceutical for Prostate Cancer Diagnosis in Korea
[Asia Economy Reporter Minji Lee] FutureChem announced on the 26th that it has submitted an Investigational New Drug (IND) application for the domestic Phase 3 clinical trial of the diagnostic radiopharmaceutical Florastamin FC303, targeting high-risk prostate cancer patients, to the Ministry of Food and Drug Safety.
Hot Picks Today
"Is Yours Just Gathering Dust at Home? Millenni...
- "Stock Set to Double: This Company Smiles Every Time a Data Center Is Built [Cli...
- "Continuous Groundwater Pumping Causes Mexico City to Sink 24cm Annually... 'Gia...
- "I Take Full Responsibility"... Seongjae Ahn Issues Direct Apology for 'Wine Swi...
- “She Shouted, ‘The Rope Isn’t Tied!’... Chinese Woman Falls from 168m Cliff ...
The company stated, "Using radiopharmaceuticals for diagnosis allows imaging of lesions at the molecular level, making it possible to detect prostate cancer lesions even when the lesions are small or PSA levels are low," and added, "Clinical trials are planned to be conducted at a total of seven institutions."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
